TITLE

Dosage discovery

AUTHOR(S)
Hewitt, Allison
PUB. DATE
December 1997
SOURCE
Pharmaceutical Executive;Dec97, Vol. 17 Issue 12, p88
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the result of Elan's multicenter, double-blind, placebo-controlled Phase II safety, tolerability, dose-selection, and efficacy study of Neurobloc in patients with cervical dystonia. Comparison of placebo-treated patients to those receiving single injection of Neurobloc; Duration of the effect.
ACCESSION #
115609

 

Related Articles

  • Smiling Irish eyes. Gopal, Kevin // Pharmaceutical Executive;Sep97, Vol. 17 Issue 9, p40 

    Provides an overview on the strong financial performance of Ireland-based Elan Corp. Transition of the company from a licensing and contract manufacturing operation to a biopharmaceutical firm; Rise of Elan's product sales; Expansion plans of the company.

  • Elan Corp. Injects $300 Million Into Market. Hahn, Tamar // Private Placement Letter;06/07/99, Vol. 17 Issue 23, p2 

    Reports that Elan Corp. PLC is in the market with $300 million transaction. Maturity of the subordinated notes; Business operation of Elan; Sales reported by Elan for 1998.

  • Another drug approved as adjunctive therapy for seizures. MAill-Lewis, Jillene // Drug Topics;4/17/2000, Vol. 144 Issue 8, p34 

    Introduces antiepileptic drug Zonisamide or Zonegran marketed by Elan Pharmaceuticals company. Mechanism of action of the drug; Factors that can limit its usefulness.

  • Elan Sells $850M in HY. Sheahan, Matthew // High Yield Report;5/27/2013, p51 

    The article reports on the decision of Irish biotechnology firm Elan to increase its loan offering to 850 million U.S. dollars in May 2013.

  • Elan Pharma restructures UK business.  // Life Science Today;Apr2000, Vol. 1 Issue 2, p2 

    Reports on the restructuring plans of Elan Pharma Ltd. in Great Britain. Responsibilities of the four business units established; Appointment of Ian Ellis to head the Athena Neurosciences business unit.

  • Elan turns to loss in Q4.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p18 

    No abstract available.

  • Elan nicotine patch to switch to OTC, private-label form. Levy, Sandra // Drug Topics;2/15/99, Vol. 143 Issue 4, p16 

    Reports that Elan Corp. received a United States Food and Drug Administration approval to change its nicotine transdermal system patch from prescription to over-the-counter (OTC) status. How the product will be marketed; OTC introduction of Elan patch in line with trend in the market place;...

  • Open Book Policy Backfires. Burns, Mairin // Investment Dealers' Digest;02/11/2002, Vol. 68 Issue 6, p12 

    Reports the lawsuits resulting from the decision of Irish pharmaceuticals group Elan Corp. to open balance sheets in the United States. Problem with the effort to clarify the accounting system; Failure of the company to meet the accounting standard of the country; Impact on the pace of product...

  • EDC Set on Drawing Elan Corp. to Sorrento Valley. Webb, Marion // San Diego Business Journal;6/18/2001, Vol. 22 Issue 25, p3 

    Reports the relocation of Elan Corp. to Sorrento Valley by EDC in San Diego, California. Doubts on employee relocation; Advantages of the consolidation of Elan and Dura Pharmaceutical in competing with New Jersey pharmaceutical; Expansion in terms of employees; Focus of the company.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics